Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Risk management needed for nano medical technology, says senior devices expert

This article was originally published in Clinica

Executive Summary

A comprehensive and systematic risk management-based approach, rather than a prescriptive regulatory approach, is essential for the future development and success of nano-and other novel medical technologies both from the point of view of promoting innovation and of safeguarding public health. That is the view of Richard Moore, manager, nanomedicine and life sciences, at Europe's major nanotechnology information centre, the Institute of Nanotechnology (IoN), based in Scotland. Mr Moore, has only recently joined the IoN, after working as director of science and innovation at the European medtech industry association, Eucomed, for nearly 10 years. He was previously with the European Committee for Standardisation as project manager, healthcare, for six years before taking up the Eucomed job, and told Clinica that he is "glad that he can offer his expertise in medical nanotechnology to the institute". He sees many challenges ahead in this field where technological progress is leaping ahead, with regulation struggling to keep up. Understanding the real risks associated with these products is proving complex.

You may also be interested in...

Keep Makena Under Accelerated Approval Pending More Studies, AMAG Tells US FDA

AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.

World-First Nod For Yuhan's Lung Cancer Drug, In Korea

The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.

DePuy Synthes Gains US FDA Clearance For Velys Robot For Total Knee Surgery

DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts